display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
endometrial cancer - (neo)adjuvant (NA)
endometrial cancer - (neo)adjuvant (NA)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus SoC KEYNOTE-B21

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons